-
About NERA
Since 1961, NERA has provided unparalleled guidance on the most important market, legal, and regulatory questions of the day. Our work has shaped industries and policy around the world. Our field-leading experts and deep experience allows us to provide rigorous analysis, reliable expert testimony, and data-powered policy recommendations for the world’s leading law firms and corporations as well as regulators and governments. Our experience, integrity, and economic ingenuity mean you can depend on us in the face of your biggest economic and financial challenges.
New York City, New York—NERA is pleased to announce two articles written by our experts have been nominated for the 2026 Antitrust Writing Awards in the General Economics category.
The first article, “Lessons in Evaluation: Shaping Successful Policy, Business Decisions, and Legal Outcomes” by Senior Managing Director Daniel Hanson, Consultant Kajal Kumar, Analyst Margot Cintract, and Affiliated Consultant Francis Ostermeijer, examines how evaluation techniques can support policymakers, courts, and businesses in navigating complex decisions. The authors offer guidance on choosing credible methods and avoiding common pitfalls and highlight the role evaluation plays in shaping policy and resolving legal disputes.
The second article, “Looking for Patterns in Pharmaceuticals’ Use of AI Patents” by Consultant Kiefer Ahn, explores pharmaceutical patent applications that incorporate AI components, using USPTO and AIPD data to identify emerging trends. The paper highlights the importance of these developments for innovation, regulatory policy, and competition in AI-focused industries.
The Antitrust Writing Awards, organized by Concurrences and the George Washington University, recognizes the best antitrust, law, and economics articles of the previous year to promote scholarship in competition.
Read and vote for “Lessons in Evaluation: Shaping Successful Policy, Business Decisions, and Legal Outcomes” here.
Read and vote for “Looking for Patterns in Pharmaceuticals’ Use of AI Patents” here.